Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer
AgElOn
1 other identifier
interventional
296
1 country
1
Brief Summary
The aim of the study is to evaluate frailty in patients aged ≥ 65 years with cancer. The elderly population is very heterogeneous, it is necessary to evaluate these elderly patients before treatment to assess the risk-benefit balance. To date, this assessment relies on subjective clinical methods often not optimal, and slow to implement. An innovative method of evaluation could be the determination of elastin peptides. Indeed, the rate of these peptides, which are linked to serious conditions associated with age, rising inexorably with age and dose could help determine more objectively the type of treatment to offer older patients. Expected results : This study will allow better identification of the group of frail elderly through more relevant biological marker that clinical assessment, often subjective and not available within a period compatible with the treatment of newly diagnosed cancer. This biological assessment will also enable optimal management of elderly patients in particular by allowing the geriatrician better efficiency.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable cancer
Started Jan 2014
Longer than P75 for not_applicable cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 29, 2014
CompletedFirst Submitted
Initial submission to the registry
June 16, 2016
CompletedFirst Posted
Study publicly available on registry
June 21, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 16, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 16, 2023
CompletedJanuary 21, 2026
January 1, 2025
9 years
June 16, 2016
January 19, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
elastin peptides quantification
up to 36 months
Study Arms (1)
patients
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- years or older
- diagnosis of cancer
- affiliation to a social security scheme
- Signed informed consent for the study and for the collection of biological samples
You may not qualify if:
- Patient protected by law (guardianship, trusteeship)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- CHU de Reimslead
Study Sites (1)
Damien JOLLY
Reims, 51092, France
Related Publications (1)
Salesse S, Odoul L, Chazee L, Garbar C, Duca L, Martiny L, Mahmoudi R, Debelle L. Elastin molecular aging promotes MDA-MB-231 breast cancer cell invasiveness. FEBS Open Bio. 2018 Aug 2;8(9):1395-1404. doi: 10.1002/2211-5463.12455. eCollection 2018 Sep.
PMID: 30186741BACKGROUND
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 16, 2016
First Posted
June 21, 2016
Study Start
January 29, 2014
Primary Completion
January 16, 2023
Study Completion
January 16, 2023
Last Updated
January 21, 2026
Record last verified: 2025-01